Sector News

Allergan buy Salix? Not so fast, say investors intent on Valeant vote

September 29, 2014
Life sciences
Valeant Pharmaceuticals isn’t the only one who thinks Allergan should hold off on dealmaking till shareholders say their piece at a December special meeting. Three top-15 Allergan shareholders are urging the Botox maker to delay until investors weigh in on Valeant’s hostile bid.
 
The shareholder demands follow news last week that Allergan had been “closing in on” a deal for Salix Pharmaceuticals–and that the deal could thwart Valeant’s buyout efforts. On Sunday, Jeff Van Harte, CEO of eighth-largest Allergan shareholder Jackson Square, accused Allergan’s board of focusing on “hastily closing a large acquisition.”
 
“This approach appears to be intended to not only preempt shareholder approval, but also eliminate interest from the various bidders for the company,” he wrote in a letter to Michael Gallagher, Allergan’s lead independent director.
 
His concerns echoed those voiced Friday by No. 3 shareholder T. Rowe Price Group and No. 12 shareholder Pentwater Capital Management, which said Allergan shouldn’t proceed with any premeeting pickups–even those of the all-cash variety, which normally don’t require a vote–without shareholder approval, Bloomberg reports.
 
That way, shareholders would have the opportunity to vote on a new, Valeant-deal-friendly slate of directors, proposed by the Canadian pharma’s buyout partner, Bill Ackman.
 
“Over the past several months, we have been watching with growing concern the corporate governance practices of the Allergan board,” T. Rowe spokesman Bill Benintende said in a statement seen by the news service. “The issues to be voted on at the special meeting of shareholders on Dec. 18 are of such importance that they impose a special duty on the board to refrain from approving any significant, irreversible commitments by the company between now and then unless shareholders are offered the opportunity to vote on them.”
 
Of course, there’s no guarantee Allergan will have a chance to snag Salix–or another Valeant blocker–before then anyway. At least one of the California company’s rumored buyout targets, Shire ($SHPG), has already been snapped up since the Valeant/Allergan saga began. And though Allergan/Salix talks have reportedly been going on for weeks now, CNBC reported last week that Actavis ($ACT)–which at one point offered to buy Allergan itself–has now moved in on the North Carolina drugmaker.
 
But if an Allergan deal for Salix does go through, Ackman will be ready. In that instance, he’ll “immediately bring litigation” against Allergan and “any counterparty that aids and abets” it for breach of fiduciary duty.
 
By Carly Helfand
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend